On June 24, 2013, the United States Supreme Court issued its decision in Mutual Pharmaceutical Company, Inc. v. Bartlett holding that state-law design defect claims against generic pharmaceutical manufacturers are preempted by federal law. Join Reed Smith attorney James Beck and other commentators for this roundtable discussion to learn about the significance of the Bartlett decision and its impact on the Court’s preemption holdings.